Ana Alfirevic is Professor Emerita of Pharmacology and Personalised Medicine at the University of Liverpool, UK. She received an MD at the University of Zagreb Medical School. In 2005, she received a PhD in Pharmacology at the University of Liverpool. Since then, she has been working in The Wolfson Centre for Personalised Medicine at the Department of Pharmacology and Therapeutics, University of Liverpool. Her research has been focused on the molecular pharmacology and pharmacogenetics. She has been working on several projects on identification of genetic predisposing factors for drug-induced hypersensitivity reactions and hepatotoxicity using high throughput genotyping and sequencing methodologies. She has also developed an interest in safety pharmacogenetics of cardiovascular diseases, in particular with lipid lowering therapy, anticoagulants and antiplatelet drugs. She has also focused her research in the area of implementing new technologies for point of care diagnostics into clinical practice through the National Institute of Health Research Collaboration for Leadership in Applied Health Research and Care, which brings universities, local authorities, NHS organisations and the public together to accelerate the translation of research findings into health service improvements.